Recombinant Biotinylated Human LILRB1 / CD85j / ILT2 Protein, Fc,Avitag™, 25 µg

Background
LILRB1 (Uniprot No. D9IDM8-1) is a variant that correlates with the low expression of LILRB1 on NK cells. It reflects the diversity of the LILRB1 locus and its influences on expression patterns on NK cells. LILRB1 belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity.

Source
Recombinant Biotinylated Human LILRB1, Fc,Avitag (CDJ-H82F7) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - His 458 (Accession # D9IDM8-1).
Predicted N-terminus: Gly 24

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™)
The protein has a calculated MW of 75.6 kDa. The protein migrates as 100-116 kDa under reducing (R) condition, and 150 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Clinicopathologic features of relapsed CD19(-) B-ALL in CD19-targeted immunotherapy: Biological insights into relapse and LILRB1 as a novel B-cell marker for CD19(-) B lymphoblasts"
Chen, Fuda, Rosado et al
Int J Lab Hematol (2024)
(2) "HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity"
Bassan, Weinberger, Yi et al
J Immunother Cancer (2023) 11 (12)
(3)  "Overall avidity declines in TCR repertoires during latent CMV but not EBV infection"
Couturaud, Doix, Carretero-Iglesia et al
Front Immunol (2023) 14, 1293090
Showing 1-3 of 403 papers.